PureTech Health (PRTC) Net Income towards Common Stockholders (2024 - 2025)
PureTech Health (PRTC) reported Net Income towards Common Stockholders of -$44.6 million for Q2 2025, down 6.78% on a QoQ basis from -$41.8 million in Q4 2024.
PureTech Health (PRTC) has 2 years of Net Income towards Common Stockholders data on file, last reported at -$44.6 million in Q2 2025.
- Quarterly Net Income towards Common Stockholders changed N/A year-over-year to -$44.6 million in Q2 2025, while the trailing twelve-month figure through Dec 2025 was -$86.4 million (down 106.78% YoY) and the FY2025 annual result came in at -$109.7 million, down 305.08% from the prior year.
- Net Income towards Common Stockholders retreated to -$44.6 million in Q2 2025 per PRTC's latest filing, from -$41.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$41.8 million in Q4 2024 and bottomed at -$44.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.63 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -44.61 Mn |
| Dec 31, 2024 | -41.77 Mn |